Patienter bør monitoreres for pulmonale symptomer, der indikerer interstitiel lungesygdom (f. eks. hoste, feber, dyspnø og/ eller hypoxia), og topotecan bør seponeres, hvis en ny diagnose af ILD er bekræftet.
Patients should be monitored for pulmonary symptoms indicative of interstitial lung disease (e. g. cough, fever, dyspnoea and/ or hypoxia), and topotecan should be discontinued if a new diagnosis of 27 ILD is confirmed.